Sevoflurane

證據等級: L5

預測適應症: 10 個

Sevoflurane: From General Anesthesia to Prinzmetal Angina

One-Sentence Summary

Sevoflurane is a fluorinated volatile inhalation agent widely used for the induction and maintenance of general anesthesia in surgical settings. The TxGNN model predicts it may be effective for Prinzmetal Angina (vasospastic angina), with 0 clinical trials and 0 publications currently supporting this direction — making this a model-only prediction at this stage.

Quick Overview

Item	Content
Original Indication	Inhalation general anesthetic (not formally registered in the Philippines; 0 active licenses on record)
Predicted New Indication	Prinzmetal Angina
TxGNN Prediction Score	99.78%
Evidence Level	L5
Philippines Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the current Evidence Pack. Based on known pharmacological class information, Sevoflurane is a halogenated ether inhalation anesthetic that produces general anesthesia through multiple ion channel effects — including enhancement of GABA-A receptor activity, inhibition of NMDA receptors, and activation of ATP-sensitive potassium (K_{ATP}) channels.

The K_{ATP} channel activation pathway is the key link to Prinzmetal angina. Sevoflurane’s activation of coronary vascular K_{ATP} channels promotes coronary artery vasodilation and triggers ischemic preconditioning — a cardioprotective phenomenon that theoretically counteracts the pathological coronary artery spasm underlying Prinzmetal angina. This is a mechanistically plausible, though indirect, connection.

However, the clinical translation pathway is critically limited. Sevoflurane is exclusively an inhalation agent requiring specialized vaporizer equipment and monitored anesthesia conditions. Prinzmetal angina is a chronic episodic condition requiring either acute rescue or long-term prophylactic therapy — neither of which is achievable with an inhaled anesthetic. The mechanistic link exists on paper, but the route of administration poses an insurmountable practical barrier to repurposing.

Clinical Trial Evidence

Currently no related clinical trials registered for Sevoflurane in Prinzmetal Angina.

Literature Evidence

Currently no related literature available for Sevoflurane in Prinzmetal Angina.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: This is a purely model-driven prediction (L5) with zero supporting clinical trials or literature. While the K_{ATP} channel mechanism provides a theoretical link to coronary vasospasm, the fundamental incompatibility between inhalation-only delivery and chronic angina management makes clinical translation not feasible without a radically different drug formulation.

To proceed, the following is needed:

Detailed MOA data from DrugBank (DG002) to confirm K_{ATP} channel involvement
TFDA/Philippines FDA package insert to retrieve formal warnings and contraindications (DG001)
A credible alternative delivery concept (e.g., inhaled sevoflurane as acute abort therapy for refractory vasospastic episodes in a monitored setting) before any research pathway can be proposed
Literature search specifically targeting volatile anesthetics + coronary vasospasm + ischemic preconditioning to determine whether any translational case reports exist outside this dataset’s capture window

⚠️ Disclaimer: This report is generated for research reference purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before any application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.